Clinical trials: Ticagrelor
Coronary Artery Disease
Effects of Low-dose Ticagrelor vs. Clopidogrel in Stable Patients Undergoing Elective Percutaneous Coronary Intervention
The proposed study aims to assess the antiplatelet effects of more potent oral P2Y12 inhibition with low-dose ticagrelor (60 mg bid) compared with standard of care clopidogrel in patients with a high ABCD-GENE score (≥10).
- Trial name
- NCT06228456
- Testing
- Ticagrelor 60mg, Clopidogrel
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Florida
ST Elevation Myocardial Infarction, No-Reflow Phenomenon
Rivaroxaban for Slow Coronary Flow After PCI in STEMI
The goal of this clinical trial is to learn if drug Rivaroxaban works to improve slow flow in STEMI patients after PCI in adults. It will also learn about the safety of drug Rivaroxaban.
- Trial name
- NCT07195812
- Testing
- Dual Antiplatelet (DAPT) Therapy, Rivaroxaban
- Volunteers
- 60 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Ischemic Stroke
Combining Aspirin With Ticagrelor or Cilostazol in Large-vessel Minor Stroke or TIA
Along with the current clinical trial, the efficacy and safety of a 180 mg loading dose of ticagrelor administered within 24 hours of the first-ever large-vessel minor stroke or TIA compared to 200mg cilostazol were assessed…
- Trial name
- NCT06591377
- Testing
- Ticagrelor 90 MG, Cilostazol 100 MG, Aspirin 75mg
- Where
- 2 sites in Egypt
- Volunteers
- 900 people
- Sponsor
- Kafrelsheikh University
Acute Coronary Syndromes
Utilization of Ticagrelor in the Upstream Setting for Non-ST-Segment Elevation Myocardial Infarction (UPSTREAM): An ED-Based Clinical Registry
The primary objective of the UPSTREAM Registry is to address the data gap regarding the course of NSTEMI (Non-ST-Elevation Myocardial Infarction)between ED (Emergency Department) arrival and diagnostic angiography in detail, by…
- Trial name
- NCT02271022
- Testing
- Non-Interventional Study
- Where
- 55 sites in United States
- Volunteers
- 2,000 people
- Sponsor
- AstraZeneca
Acute Coronary Syndromes, Non ST Elevation Myocardial Infarction
Sub Lingual Versus Traditional Oral Administration of Ticagrelor in Acute Coronary Syndrome/Non ST-elevation Myocardial Infarction - A Platelet Reactivity Study
Our goal is to examine sub lingual versus traditional oral administration of ticagrelor in ACS/non ST-elevation Myocardial Infarction (NSTEMI) patients on platelet reactivity.
- Trial name
- NCT02402400
- Testing
- Sub Lingual Ticagrelor
- Where
- Israel
- Volunteers
- 50 people
- Sponsor
- Sheba Medical Center
Pharmacokinetics
KF2019#1-trial: Effects of a Thrombocyte Inhibitor on a Cholesterol-lowering Drug
The cholesterol-lowering drug rosuvastatin is a substrate of the breast cancer resistance protein (BCRP). BCRP is an efflux transporter expressed e.g. in the small intestine.
- Trial name
- KF2019#1 (NCT05373277)
- Testing
- Ticagrelor, Rosuvastatin
- Where
- Finland
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Helsinki University Central Hospital
Healthy
Study to Evaluate the Safety, Tolerability, PK, and PD of PB2452 in Healthy Volunteers
This is a Phase 1, first-in-human, randomized, double-blind, placebo-controlled, single ascending dose, sequential group study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PB2452 with and…
- Trial name
- NCT03492385
- Testing
- PB2452 Infusion, Ticagrelor Oral Tablet - Pre-Treatment, Ticagrelor Oral Tablet - Pre-Treatment and Post-Treatment
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- SFJ Pharmaceuticals, Inc.
Peripheral Arterial Disease
Ticagrelor and Peripheral Arterial Disease
This is an interventional study assessing the effectiveness of Ticagrelor on the reduction of thrombus burden using optical coherence tomography in patients undergoing peripheral artery stenting.
- Trial name
- NCT02407314
- Testing
- Percutaneous Peripheral Intervention, Optical Coherence Tomography, Ankle Brachial Index
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Arkansas Heart Hospital
Coronary Artery Disease, Myocardial Infarction
Bedside Testing of CYP2C19 Gene for Treatment of Patients With PCI With Antiplatelet Therapy
Clopidogrel is crucial as antiplatelet treatment in patients undergoing percutaneous coronary intervention (PCI) with stent implantation and during one year after PCI, to prevent atherothrombotic complications.
- Conditions
- Coronary Artery Disease, Myocardial Infarction, Heart Disease, Vascular Disease
- Trial name
- NCT01823185
- Testing
- clopidogrel, Ticagrelor or prasugrel
- Where
- 4 sites in Saudi Arabia
- Volunteers
- 1,500 people
- Sponsor
- Imam Abdulrahman Bin Faisal University
Chronic Obstructive Pulmonary Disease (COPD)
Anti-platelet Therapy in the Prevention of Cardiovascular Disease in Patients With COPD (APPLE-COPD: ICON 2)
Patients with COPD (chronic bronchitis and/or emphysema) are known to be at an increased risk of heart disease and death due to heart attacks.
- Trial name
- NCT03487406
- Testing
- Ticagrelor, Aspirin
- Where
- United Kingdom
- Volunteers
- 120 people
- Sponsor
- Newcastle-upon-Tyne Hospitals NHS Trust
Healthy
Ticagrelor and Adenosine
Preclinical studies have shown that the P2Y12 receptor antagonist ticagrelor can increase the extracellular concentration of the endogenous nucleoside adenosine by inhibiting the cellular uptake of adenosine via the equilibrative…
- Trial name
- NCT01996735
- Testing
- Ticagrelor 180 mg single dose
- Where
- Netherlands
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Myocardial Infarction
A Study to Evaluate the Use of Mobile-phone Based Patient Support in Patients Diagnosed With Myocardial Infarction
The purpose of this study is to evaluate whether the mobile-phone based patient support has an impact on the adherence and persistence of ticagrelor treatment or on lifestyle changes that will have a positive impact on the…
- Trial name
- SUPPORT (NCT01874262)
- Testing
- Mobile-phone based patient support, e-diary
- Where
- 13 sites in Sweden
- Volunteers
- 174 people
- Sponsor
- AstraZeneca
Myocardial Infarction (MI)
Patient Characteristics, Persistence to Treatment and Outcome Events in Patients Treated With Ticagrelor 60 mg After Myocardial Infarction in Real-world Clinical Practice
This is an observational study based on secondary data extracted from multiple register-based data sources in the US and Europe (Sweden, United Kingdom, Italy, Germany).
- Trial name
- ALETHEIA (NCT04568083)
- Where
- 6 sites in United States, Germany and 3 more
- Volunteers
- 7,035 people
- Sponsor
- AstraZeneca
ST-segment Elevation Myocardial Infarction, Non-ST-segment Elevation Myocardial Infarction
Influence of Morphine on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients With Acute Myocardial Infarction
The purpose of the IMPRESSION study is to determine whether intravenous administration of morphine prior to ticagrelor administration in ST-segment elevation myocardial infarction (STEMI) patients and in non-ST-segment elevation…
- Conditions
- ST-segment Elevation Myocardial Infarction, Non-ST-segment Elevation Myocardial Infarction, VA Drug Interactions
- Trial name
- IMPRESSION (NCT02217878)
- Testing
- Morphine, Ticagrelor
- Where
- Poland
- Volunteers
- 74 people
- Sponsor
- Collegium Medicum w Bydgoszczy
Chronic Total Occlusion of Coronary Artery
To Evaluate Whether IVUS-guided Drug-eluting Stent (DES) Implantation Leads to Better Clinical Outcomes Compared to Conventional Angiography in the Treatment of Chronic Complete Occlusion (CTO) Disease.
This study aims to evaluate the treatment of Chronic total occlusion (CTO) disease. Whether Intravascular Ultrasonography (IVUS) guiding the implantation of drug-eluting stents (DES) will provide better long-term clinical…
- Trial name
- CRUISE-CTO (NCT04944615)
- Testing
- The guidewire successfully passed the CTO lesion
- Where
- China
- Volunteers
- 1,448 people
- Sponsor
- CCRF Inc., Beijing, China
Acute Coronary Syndrome, Myocardial Infarction
Cangrelor vs. Ticagrelor for Early Platelet Inhibition in STEMI
This randomized, controlled trial compares the anti-thrombotic effect of cangrelor and ticagrelor on platelet activity in patients with acute ST-elevation myocardial infarction.
- Conditions
- Acute Coronary Syndrome, Myocardial Infarction, STEMI - ST Elevation Myocardial Infarction
- Trial name
- CanTi (NCT03182855)
- Testing
- Ticagrelor, Cangrelor Tetrasodium
- Where
- Denmark
- Volunteers
- 80 people
- Sponsor
- University of Aarhus
Acute Coronary Syndrome
Efficacy and Safety Study of Ticagrelor
The purpose of this study is to compare the efficacy and safety of ticagrelor with clopidogrel
- Trial name
- NCT01812330
- Testing
- Clopidogrel, Ticagrelor
- Where
- China
- Volunteers
- 180 people
- Sponsor
- General Hospital of Chinese Armed Police Forces
Coronary Artery Disease, Ticagrelor
The Optimal Strategy of Switching From Clopidogrel to Ticagrelor in Patients With Complexity of Coronary Artery Disease
The study is to further exploring the optimal switching strategy by evaluating the pharmacodynamic responses as well as adverse events in patients with complexity of coronary artery disease managed by percutaneous coronary…
- Trial name
- NCT03577652
- Testing
- Ticagrelor
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Shenyang Northern Hospital
Microvascular Angina
Effect of Ticagrelor on Adenosine-Induced Coronary Flow Reserve in Patients With Microvascular Angina
This study is undertaken to determine if ticagrelor augments adenosine-induced coronary flow reserve (CFR), ameliorates clinical symptomatology and exercise tolerance in patients with MVA
- Trial name
- NCT02284048
- Testing
- ticagrelor
- Volunteers
- 140 people
- Sponsor
- Second Xiangya Hospital of Central South University
Multi Vessel Coronary Artery Disease
Dual Antiplatelet Therapy in Patients With Clopidogrel Resistance Following Off-Pump Coronary Artery Bypass
Ticagrelor, a direct-acting oral P2Y12-receptor antagonist, provides greater and more consistent platelet inhibition than clopidogrel.
- Trial name
- NCT05166538
- Testing
- Ticagrelor, Clopidogrel
- Where
- South Korea
- Volunteers
- 204 people
- Sponsor
- Yonsei University